EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

ZIF-8 with encapsulated dihydroartemisinin in a drug delivery system for protection against Plasmodium berghei ANKA-induced experimental cerebral malaria in C57BL/6N mice

Yuting Li, Liu-Gen Li, Huiyin Zhu, Daiqian Zhu, Haimei Shi, Wei Wang iD, Jinyu Mo, Jianhai Yin iD, Tong-Fei Li iD, Jian Li iD

Microbiology Spectrum · 2025

DOI: 10.1128/spectrum.02366-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Microbiology Spectrum, 2025. Verfasst von Yuting Li und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Basic Medical Sciences, Hubei University of Medicine, Shiyan, Hubei, China. Hauptthemen laut MEDLINE: Malaria, Cerebral, Artemisinins, Plasmodium berghei, Antimalarials. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cerebral malaria (CM), primarily caused by Plasmodium falciparum , is the primary cause of malaria-related fatalities. CM treatment faces significant challenges due to limited therapeutic options and the emergence of antimalarial drug resistance. Dihydroartemisinin (DHA) is the first-line therapeutic agent for malaria. However, it encounters limitations such as poor solubility, inadequate selectivity, and rapid elimination. Here, we introduced a facile and effective approach using zeolite imidazolium framework-8 (ZIF-8) encapsulated with DHA (DHA@ZIF-8) and assessed its therapeutic efficacy in an experimental cerebral malaria model. The DHA@ZIF-8 demonstrated excellent drug-loading capacity, high stability, prolonged drug release, and improved targeted elimination of Plasmodium parasites within infected red blood cells (iRBCs). This minimized damage to brain microvascular endothelial cells (BMECs) and protected organs from injury, increasing the survival time of the infected mice. Compared to free DHA, DHA@ZIF-8 exhibited better antimalarial efficacy and almost no side effects. This study highlights ZIF-8’s potential as a reliable, stable, and efficient drug delivery vector for DHA to improve CM therapy. IMPORTANCE For the treatment of human malaria, artemisinin-based drugs remain the first-line treatment option. However, their utility is constrained by their short half-life in vivo . Consequently, extending the duration for drug efficacy in the body is a critical issue that needs to be addressed. Metal-organic frameworks are a promising choice for drug loading. In the present study, DHA@ZIF-8 and DHA@MOF were constructed and characterized and were assessed in an experimental cerebral malaria model of C57BL/6 N mice induced by Plasmodium berghei ANKA strain. Data show that DHA@ZIF-8 has a worthy therapeutic effect on experimental cerebral malaria. It will offer a new option for human cerebral malaria (HCM) treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Malaria, CerebralArtemisininsPlasmodium bergheiAntimalarialsDrug Delivery SystemsZeolitesAnimalsMiceMice, Inbred C57BLDisease Models, AnimalEndothelial CellsDrug CarriersErythrocytesDrug LiberationFemaleHumans

Stichwörter der Autor:innen

cerebral malariadihydroartemisinindrug deliverynanodrugzeolitic imidazolate framework-8

Substanzen

artenimolArtemisininsAntimalarialsZeolitesDrug Carriers

Autor:innen und Institutionen

  • School of Basic Medical Sciences, Hubei University of Medicine, Shiyan, Hubei, China.
  • Key Laboratory of National Health Commission on Parasitic Disease Prevention and Control, Jiangsu Provincial Key Laboratory on Parasites and Vector Control Technology, Jiangsu Institute of Parasitic Diseases, Wuxi, Jian…
  • National Institute of Parasitic Diseases, Chinese Center for Disease Control and Prevention (Chinese Center for Tropical Diseases Research), NHC Key Laboratory of Parasite and Vector Biology, WHO Collaborating Centre fo…

ORCID-Profile: Wei Wang, Jianhai Yin, Tong-Fei Li, Jian Li

Zitieren

APA

Li, Y., Li, L. G., Zhu, H., Zhu, D., Shi, H., Wang, W., Mo, J., Yin, J., Li, T., & Li, J. (2025). ZIF-8 with encapsulated dihydroartemisinin in a drug delivery system for protection against Plasmodium berghei ANKA-induced experimental cerebral malaria in C57BL/6N mice. Microbiology Spectrum. https://doi.org/10.1128/spectrum.02366-24

Vancouver

Li Y, Li LG, Zhu H, Zhu D, Shi H, Wang W, et al. ZIF-8 with encapsulated dihydroartemisinin in a drug delivery system for protection against Plasmodium berghei ANKA-induced experimental cerebral malaria in C57BL/6N mice. Microbiology Spectrum. 2025. doi:10.1128/spectrum.02366-24

BibTeX
@article{Li2025,
  author = {Li, Yuting and Li, Liu-Gen and Zhu, Huiyin and Zhu, Daiqian and Shi, Haimei and Wang, Wei and Mo, Jinyu and Yin, Jianhai and Li, Tong-Fei and Li, Jian},
  title = {ZIF-8 with encapsulated dihydroartemisinin in a drug delivery system for protection against Plasmodium berghei ANKA-induced experimental cerebral malaria in C57BL/6N mice},
  journal = {Microbiology Spectrum},
  year = {2025},
  doi = {10.1128/spectrum.02366-24}
}
Kostenlos starten →